Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER_GOV 2OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Fallopian Tube Neoplasms 2Ovarian Neoplasms 1

Interventions

Cisplatin 10apatinib 5Surgical Procedures, Operative 4Radiotherapy 4Paclitaxel 4Hyperthermic Intraperitoneal Chemotherapy 4Hydralazine 4Gemcitabine 4Carboplatin 4Valproic Acid 3Neoadjuvant Therapy 3Drug Therapy 3Bevacizumab 3taxane 2pembrolizumab 2cetrorelix 2Radiotherapy, Intensity-Modulated 2Probiotics 2Population Groups 2Poly(ADP-ribose) Polymerase Inhibitors 2Metformin 2Laparoscopy 2Indocyanine Green 2Etoposide 2Curcumin 2CP protocol 2Brachytherapy 2spartalizumab 1piperine 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × taxane × Gynecologic × Clear all
NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

NCT01669226 2016-12-19

AICE

Shanghai Gynecologic Oncology Group

Phase 2 Completed
215 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡